Literature DB >> 10086385

Neuroprotection by a caspase inhibitor in acute bacterial meningitis.

J S Braun1, R Novak, K H Herzog, S M Bodner, J L Cleveland, E I Tuomanen.   

Abstract

Half of the survivors of bacterial meningitis experience motor deficits, seizures, hearing loss or cognitive impairment, despite adequate bacterial killing by antibiotics. We demonstrate that the broad-spectrum caspase inhibitor N-benzyloxycarbonyl-Val-Ala-Asp-fluoromethyl-ketone (z-VAD-fmk) prevented hippocampal neuronal cell death and white blood cell influx into the cerebrospinal fluid compartment in experimental pneumococcal meningitis. Hippocampal neuronal death was due to apoptosis derived from the inflammatory response in the cerebrospinal fluid. Apoptosis was induced in vitro in human neurons by inflamed cerebrospinal fluid and was blocked by z-VAD-fmk. As apoptosis drives neuronal loss in pneumococcal meningitis, caspase inhibitors might provide a new therapeutic option directed specifically at reducing brain damage.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10086385     DOI: 10.1038/6514

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  73 in total

1.  Pneumococcal pneumolysin and H(2)O(2) mediate brain cell apoptosis during meningitis.

Authors:  Johann S Braun; Jack E Sublett; Dorette Freyer; Tim J Mitchell; John L Cleveland; Elaine I Tuomanen; Joerg R Weber
Journal:  J Clin Invest       Date:  2002-01       Impact factor: 14.808

2.  Protection from lethal apoptosis in lipopolysaccharide-induced acute lung injury in mice by a caspase inhibitor.

Authors:  M Kawasaki; K Kuwano; N Hagimoto; T Matsuba; R Kunitake; T Tanaka; T Maeyama; N Hara
Journal:  Am J Pathol       Date:  2000-08       Impact factor: 4.307

3.  HIV-1 envelope induces activation of caspase-3 and cleavage of focal adhesion kinase in primary human CD4(+) T cells.

Authors:  C Cicala; J Arthos; A Rubbert; S Selig; K Wildt; O J Cohen; A S Fauci
Journal:  Proc Natl Acad Sci U S A       Date:  2000-02-01       Impact factor: 11.205

Review 4.  Reprogramming the host response in bacterial meningitis: how best to improve outcome?

Authors:  M van der Flier; S P M Geelen; J L L Kimpen; I M Hoepelman; E I Tuomanen
Journal:  Clin Microbiol Rev       Date:  2003-07       Impact factor: 26.132

5.  Experimental pneumococcal meningitis: impaired clearance of bacteria from the blood due to increased apoptosis in the spleen in Bcl-2-deficient mice.

Authors:  Andreas Wellmer; Matthias von Mering; Annette Spreer; Ricarda Diem; Helmut Eiffert; Christiane Noeske; Stefanie Bunkowski; Ralf Gold; Roland Nau
Journal:  Infect Immun       Date:  2004-06       Impact factor: 3.441

Review 6.  Myeloid Cells in the Central Nervous System.

Authors:  Jasmin Herz; Anthony J Filiano; Ashtyn Smith; Nir Yogev; Jonathan Kipnis
Journal:  Immunity       Date:  2017-06-20       Impact factor: 31.745

7.  Antioxidant treatment prevents cognitive impairment and oxidative damage in pneumococcal meningitis survivor rats.

Authors:  Tatiana Barichello; Ana Lucia B Santos; Geovana D Savi; Jaqueline S Generoso; Paola Otaran; Cleonice M Michelon; Amanda V Steckert; Francielle Mina; Clarissa M Comim; Felipe Dal-Pizzol; João Quevedo
Journal:  Metab Brain Dis       Date:  2012-05-17       Impact factor: 3.584

8.  Pathophysiology and treatment of bacterial meningitis.

Authors:  Olaf Hoffman; R Joerg Weber
Journal:  Ther Adv Neurol Disord       Date:  2009-11       Impact factor: 6.570

9.  TRAIL limits excessive host immune responses in bacterial meningitis.

Authors:  Olaf Hoffmann; Josef Priller; Timour Prozorovski; Ulf Schulze-Topphoff; Nevena Baeva; Jan D Lunemann; Orhan Aktas; Cordula Mahrhofer; Sarah Stricker; Frauke Zipp; Joerg R Weber
Journal:  J Clin Invest       Date:  2007-07       Impact factor: 14.808

10.  MX1013, a dipeptide caspase inhibitor with potent in vivo antiapoptotic activity.

Authors:  Wu Yang; John Guastella; Jin-Cheng Huang; Yan Wang; Li Zhang; Dong Xue; Minhtam Tran; Richard Woodward; Shailaja Kasibhatla; Ben Tseng; John Drewe; Sui Xiong Cai
Journal:  Br J Pharmacol       Date:  2003-08-26       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.